The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.

Billings LK, Agner BFR, Altuntas Y, Grøn R, Halladin N, Klonoff DC, Tentolouris N, Jódar E

Journal of diabetes science and technology28 Feb 2020Cited by 7 (Europe PMC)

PMID32107930PMCIDPMC8120051DOI10.1177/1932296820906888PepBankPUB-32107930

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on basal insulin, IDegLira (insulin degludec/liraglutide) gave similar HbA1c reductions to basal-bolus insulin in all subgroups.
In plain wordsIn adults with type 2 diabetes, the IDegLira combination lowered HbA1c about as much as basal-bolus insulin in every subgroup.
Peptide
Liraglutide
Outcome
No significant changeHbA1c reduction across subgroups
Study
n: not reported in source
Comparator
Basal-bolus insulin (insulin glargine and insulin aspart)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Compared with BB, and in all subgroups, IDegLira treatment consistently gave similar HbA1c reductions
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we assessed the effect of once-daily IDegLira compared with BB (once-daily insulin glargine 100 U/mL and insulin aspart ≤4 times/day) across subgroups with varying characteristics.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3210793001
02HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes on basal insulin, IDegLira (insulin degludec/liraglutide) gave less severe or blood glucose-confirmed hypoglycemia than basal-bolus insulin in all subgroups.
In plain wordsIn adults with type 2 diabetes, the IDegLira combination caused less low blood sugar than basal-bolus insulin in every subgroup.
Peptide
Liraglutide
Outcome
DecreaseSevere or blood glucose-confirmed hypoglycemia across subgroups
Study
n: not reported in source
Comparator
Basal-bolus insulin (insulin glargine and insulin aspart)
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Compared with BB, and in all subgroups, IDegLira treatment consistently gave similar HbA1c reductions, less severe or blood glucose-confirmed hypoglycemia
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we assessed the effect of once-daily IDegLira compared with BB (once-daily insulin glargine 100 U/mL and insulin aspart ≤4 times/day) across subgroups with varying characteristics.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3210793002
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on basal insulin, IDegLira (insulin degludec/liraglutide) gave a lower end-of-trial total daily insulin dose than basal-bolus insulin in all subgroups.
In plain wordsIn adults with type 2 diabetes, the IDegLira combination needed less daily insulin than basal-bolus insulin in every subgroup.
Peptide
Liraglutide
Outcome
DecreaseEnd-of-trial total daily insulin dose across subgroups
Study
n: not reported in source
Comparator
Basal-bolus insulin (insulin glargine and insulin aspart)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Compared with BB, and in all subgroups, IDegLira treatment consistently gave similar HbA1c reductions, less severe or blood glucose-confirmed hypoglycemia, lower end-of-trial (EOT) total daily insulin dose, and weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we assessed the effect of once-daily IDegLira compared with BB (once-daily insulin glargine 100 U/mL and insulin aspart ≤4 times/day) across subgroups with varying characteristics.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3210793003
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on basal insulin, IDegLira (insulin degludec/liraglutide) was linked to weight loss compared with basal-bolus insulin in all subgroups.
In plain wordsIn adults with type 2 diabetes, the IDegLira combination led to weight loss compared with basal-bolus insulin in every subgroup.
Peptide
Liraglutide
Outcome
DecreaseBody weight across subgroups
Study
n: not reported in source
Comparator
Basal-bolus insulin (insulin glargine and insulin aspart)
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Compared with BB, and in all subgroups, IDegLira treatment consistently gave similar HbA1c reductions, less severe or blood glucose-confirmed hypoglycemia, lower end-of-trial (EOT) total daily insulin dose, and weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we assessed the effect of once-daily IDegLira compared with BB (once-daily insulin glargine 100 U/mL and insulin aspart ≤4 times/day) across subgroups with varying characteristics.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3210793004
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on basal insulin, mean end-of-trial HbA1c was 53 mmol/mol or lower in all subgroups.
In plain wordsIn adults with type 2 diabetes, average HbA1c at the end of the trial was at or below the target in every subgroup.
Peptide
Liraglutide
Outcome
Not applicableEnd-of-trial HbA1c level in all subgroups
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In all subgroups, mean EOT HbA1c was ≤53 mmol/mol (≤7.0%).
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we assessed the effect of once-daily IDegLira compared with BB (once-daily insulin glargine 100 U/mL and insulin aspart ≤4 times/day) across subgroups with varying characteristics.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3210793005
06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on basal insulin, the greatest HbA1c reduction with IDegLira occurred in the highest baseline HbA1c subgroup.
In plain wordsIn adults with type 2 diabetes, the IDegLira combination lowered HbA1c most in people with the highest starting HbA1c.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction by baseline HbA1c subgroup
Study
n: not reported in source
Comparator
Other baseline HbA1c subgroups
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The greatest HbA1c reduction occurred in the highest baseline HbA1c subgroup.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we assessed the effect of once-daily IDegLira compared with BB (once-daily insulin glargine 100 U/mL and insulin aspart ≤4 times/day) across subgroups with varying characteristics.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3210793006
07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on basal insulin, mean end-of-trial daily insulin dose was 0.43 to 0.52 U/kg with IDegLira and 0.74 to 1.07 U/kg with basal-bolus insulin.
In plain wordsIn adults with type 2 diabetes, the IDegLira combination needed less daily insulin than basal-bolus insulin.
Peptide
Liraglutide
Outcome
DecreaseOverall end-of-trial daily insulin dose
Study
n: not reported in source
Comparator
Basal-bolus insulin (insulin glargine and insulin aspart)
Outcome group
Glycemic control · Metabolic and weight
Measurements
End-of-trial daily insulin dose
0.43 to 0.52 U/kg
IDegLira
End-of-trial daily insulin dose
0.74 to 1.07 U/kg
basal-bolus
Source sentences
Summary
Overall, mean EOT daily insulin dose was 0.43 to 0.52 U/kg with IDegLira and 0.74 to 1.07 U/kg with BB.
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we assessed the effect of once-daily IDegLira compared with BB (once-daily insulin glargine 100 U/mL and insulin aspart ≤4 times/day) across subgroups with varying characteristics.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3210793007
08HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on basal insulin, more participants reached the triple composite endpoint with IDegLira than with basal-bolus insulin (44.6% vs 7.0%) in the lowest baseline HbA1c subgroup.
In plain wordsIn adults with type 2 diabetes, more people met target without weight gain or low blood sugar on the IDegLira combination than on basal-bolus insulin.
Peptide
Liraglutide
Outcome
IncreaseTriple composite endpoint, baseline HbA1c at most 58.5 mmol/mol
Study
n: not reported in source
Comparator
Basal-bolus insulin (insulin glargine and insulin aspart)
Outcome group
Glycemic control · Metabolic and weight
Measurements
Triple composite endpoint
44.6%
IDegLira, HbA1c <=58.5 mmol/mol
Triple composite endpoint
7%
basal-bolus, HbA1c <=58.5 mmol/mol
Source sentences
Summary
More participants achieved the triple composite endpoint (HbA1c 58.5 to ≤69.4 mmol/mol [41.1% vs 8.3%], and >69.4 mmol/mol [23.8% vs 3.4%]).
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we assessed the effect of once-daily IDegLira compared with BB (once-daily insulin glargine 100 U/mL and insulin aspart ≤4 times/day) across subgroups with varying characteristics.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3210793008
09HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on basal insulin, more participants reached the triple composite endpoint with IDegLira than with basal-bolus insulin (41.1% vs 8.3%) in the middle baseline HbA1c subgroup.
In plain wordsIn adults with type 2 diabetes, more people met target without weight gain or low blood sugar on the IDegLira combination than on basal-bolus insulin.
Peptide
Liraglutide
Outcome
IncreaseTriple composite endpoint, baseline HbA1c above 58.5 to 69.4 mmol/mol
Study
n: not reported in source
Comparator
Basal-bolus insulin (insulin glargine and insulin aspart)
Outcome group
Glycemic control · Metabolic and weight
Measurements
Triple composite endpoint
41.1%
IDegLira, HbA1c >58.5 to <=69.4 mmol/mol
Triple composite endpoint
8.3%
basal-bolus, HbA1c >58.5 to <=69.4 mmol/mol
Source sentences
Summary
More participants achieved the triple composite endpoint (HbA1c 58.5 to ≤69.4 mmol/mol [41.1% vs 8.3%], and >69.4 mmol/mol [23.8% vs 3.4%]).
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we assessed the effect of once-daily IDegLira compared with BB (once-daily insulin glargine 100 U/mL and insulin aspart ≤4 times/day) across subgroups with varying characteristics.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3210793009
10HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on basal insulin, more participants reached the triple composite endpoint with IDegLira than with basal-bolus insulin (23.8% vs 3.4%) in the highest baseline HbA1c subgroup.
In plain wordsIn adults with type 2 diabetes, more people met target without weight gain or low blood sugar on the IDegLira combination than on basal-bolus insulin.
Peptide
Liraglutide
Outcome
IncreaseTriple composite endpoint, baseline HbA1c above 69.4 mmol/mol
Study
n: not reported in source
Comparator
Basal-bolus insulin (insulin glargine and insulin aspart)
Outcome group
Glycemic control · Metabolic and weight
Measurements
Triple composite endpoint
23.8%
IDegLira, HbA1c >69.4 mmol/mol
Triple composite endpoint
3.4%
basal-bolus, HbA1c >69.4 mmol/mol
Source sentences
Summary
More participants achieved the triple composite endpoint (HbA1c 58.5 to ≤69.4 mmol/mol [41.1% vs 8.3%], and >69.4 mmol/mol [23.8% vs 3.4%]).
1 context sentence(design, population, supporting numbers)
Summary · context
Here, we assessed the effect of once-daily IDegLira compared with BB (once-daily insulin glargine 100 U/mL and insulin aspart ≤4 times/day) across subgroups with varying characteristics.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3210793010

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02420262

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/Sn = 50626 Jul 2015 to 5 Oct 2016

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 29 Mar 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.